Dexter Successful Validation Brings Distalmotion Surgical Robot One-step Closer to Commercialization

• Around 20 surgeons and 20 nurses from leading European hospitals, across urology, gynecology, and general surgery participated in Dexter validation end of February and early March 2020
• Surgical teams successfully performed surgical procedures using Dexter, including draping, docking, suturing, dissection, switching between laparoscopy and robotics, removal and emergency scenarios

Distalmotion, a Swiss-based medical device company removing the complexity out of robotic surgery to fast track its widespread adoption in minimally invasive surgical care, announced the successful validation of its surgical robot Dexter. By confirming that it is safe for use and meets surgeons’ and nurses’ requirements, Dexter’s successful validation brings Distalmotion surgical robot Dexter one-step closer to commercialization.

The company announced that end of February and early March 2020 17 surgeons and 16 nurses from leading European hospitals, across urology, gynecology and general surgery, participated in Dexter validation first step. In this phase, surgical teams successfully performed surgical procedures using Distalmotion’s surgical robot, including draping, docking, use, switching between laparoscopy and robotics, removal and emergency scenarios. This phase confirmed Dexter performs as intended and can be used safely. As a second step, 2 urologists and 3 general surgeons performed 8 full procedures: 1 Nissen-fundoplication, 1 partial cystectomy, 3 cholecystectomies, 1 radial nephrectomy, 1 partial gastrectomy, and 1 sigmoid mobilization. This second phase confirmed Dexter’s full performance for procedures on tissues.